Trials / Unknown
UnknownNCT03522662
Anti IL-18 (GSK1070806) in Behcet's Disease
An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary outcome measure of the study is to demonstrate the safety and tolerability of GSK1070806 in the Behcet's disease population at 24 weeks, with biochemical and clinical efficacy and mechanistic studies to further explore the pathogenesis of Behcet's disease important secondary and exploratory outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1070806 | Single 10mg/kg infusion on Day 0 |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
- First posted
- 2018-05-11
- Last updated
- 2018-05-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03522662. Inclusion in this directory is not an endorsement.